Back to Search Start Over

Macrocyclic α helical peptide therapeutic modality: A perspective of learnings and challenges.

Authors :
Sawyer TK
Partridge AW
Kaan HYK
Juang YC
Lim S
Johannes C
Yuen TY
Verma C
Kannan S
Aronica P
Tan YS
Sherborne B
Ha S
Hochman J
Chen S
Surdi L
Peier A
Sauvagnat B
Dandliker PJ
Brown CJ
Ng S
Ferrer F
Lane DP
Source :
Bioorganic & medicinal chemistry [Bioorg Med Chem] 2018 Jun 01; Vol. 26 (10), pp. 2807-2815. Date of Electronic Publication: 2018 Mar 16.
Publication Year :
2018

Abstract

Macrocyclic α-helical peptides have emerged as a compelling new therapeutic modality to tackle targets confined to the intracellular compartment. Within the scope of hydrocarbon-stapling there has been significant progress to date, including the first stapled α-helical peptide to enter into clinical trials. The principal design concept of stapled α-helical peptides is to mimic a cognate (protein) ligand relative to binding its target via an α-helical interface. However, it was the proclivity of such stapled α-helical peptides to exhibit cell permeability and proteolytic stability that underscored their promise as unique macrocyclic peptide drugs for intracellular targets. This perspective highlights key learnings as well as challenges in basic research with respect to structure-based design, innovative chemistry, cell permeability and proteolytic stability that are essential to fulfill the promise of stapled α-helical peptide drug development.<br /> (Copyright © 2018. Published by Elsevier Ltd.)

Details

Language :
English
ISSN :
1464-3391
Volume :
26
Issue :
10
Database :
MEDLINE
Journal :
Bioorganic & medicinal chemistry
Publication Type :
Academic Journal
Accession number :
29598901
Full Text :
https://doi.org/10.1016/j.bmc.2018.03.008